The approval of liquid biopsy test for the diagnosis of non-small cell lung cancer (NSCLC) demonstrates how biomarker-based detection tools are becoming important components of precision medicine-based drug treatment regimes.
Precision medicine allows detailed insights into the disease processes that underlie clinical disease. This field has first started with genetics, and genetic mutation-based models that can predict disease state such as tumour phenotype or likely therapeutic response are gaining much ground in oncology.
A genetic focus to precision medicine is limited, however, as this is a largely static picture that does not capture the biological variability of disease. In recent years there has been increasing focus on downstream molecules through transcriptomics, proteomics and metabolomics. Metabolomics is particularly interesting to stratify patients to the right treatment and inform development pipelines in the future, as analysis can be performed on molecules closely linked to .........
You just need to REGISTER - its FREE - to read the rest of this article straight away.